Publications by authors named "C Tissing-Tan"
Article Synopsis
- - The study examined the real-world effects of stereotactic body radiotherapy (SBRT) in patients with stage I non-small cell lung cancer (NSCLC), focusing on acute toxicity and 90-day mortality rates among 7,279 patients treated between 2017 and 2021.
- - Acute toxicity occurred in 3.8% of patients, while 90-day mortality was at 1.7%, with certain factors like age, sex, and lung function impacting these outcomes.
- - The findings suggest that SBRT has a low rate of acute toxicity and acceptable mortality, with developed prediction models aiding in identifying patients at higher risk for adverse effects.
Introduction: Chemoradiotherapy (CRT) is the standard of care in inoperable non-small-cell lung cancer (NSCLC) patients, favoring concurrent (cCRT) over sequential CRT (seqCRT), with adjuvant immunotherapy in responders. Elderly and frail NSCLC patients have generally been excluded from trials in the past. In elderly patients however, the higher treatment related morbidity of cCRT, may outweigh the possible lower tumor control of seqCRT.
View Article and Find Full Text PDFIntroduction: Treatment patterns in stage III NSCLC can vary considerably between countries. The PACIFIC trial reported improvements in progression-free and overall survival with adjuvant durvalumab after concurrent chemoradiotherapy (CCRT). We studied treatment decision-making by three Dutch regional thoracic multidisciplinary tumor boards between 2015 and 2019, to identify changes in practice when adjuvant durvalumab became available.
View Article and Find Full Text PDFBackground And Purpose: The NVALT-11/DLCRG-02 phase III trial (clinicaltrials.gov identifier: NCT01282437) showed that, after standard curative intent treatment, prophylactic cranial irradiation (PCI) decreased the incidence of symptomatic brain metastases (BM) in stage III non-small cell lung cancer (NSCLC) patients compared to observation. In this study we assessed the impact of PCI on health-related quality of life (HRQoL).
View Article and Find Full Text PDFIntroduction: There is a lack of data on the efficacy and safety of concurrent chemoradiotherapy in elderly, limited-stage, patients with SCLC.
Methods: We compared outcomes of patients 70 years of age or older versus younger patients within the Concurrent Once-daily Versus twice-daily RadioTherapy (CONVERT) trial. Patients were randomized to receive 45 Gy/30 twice-daily fractions/19 days or 66 Gy/33 once-daily fractions/45 days concurrently with platinum-based chemotherapy.